Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Warren Olanow

Neurology

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Neurology|February 18, 2009
Can we achieve neuroprotection with currently available anti-parkinsonian interventions?C Warren Olanow
Neurology|May 24, 2006
Rationale for considering that propargylamines might be neuroprotective in Parkinson's diseaseC Warren Olanow
Neurology|March 23, 2002
The role of dopamine agonists in the treatment of early Parkinson's diseaseC Warren Olanow
Neurology|May 24, 2006
The pathogenesis of cell death in Parkinson's diseasePeter Jenner, C Warren Olanow
Neurology|January 14, 2004
Continuous dopaminergic stimulation in early and advanced Parkinson's diseaseFabrizio Stocchi, C Warren Olanow
Neurology|January 14, 2004
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?C Warren Olanow, Fabrizio Stocchi
Neurology|May 28, 2009
The scientific and clinical basis for the treatment of Parkinson disease (2009)C Warren Olanow, Matthew B Stern, Kapil Sethi
Neurology|May 24, 2006
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's diseaseBiplob Dass, C Warren Olanow, Jeffrey H Kordower
Neurology|May 24, 2006
Proteasomal dysfunction in sporadic Parkinson's diseaseKevin St P McNaught, Tehone Jackson, Ruth JnoBaptiste, et al.
Neurology|April 12, 2013
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patientsRaymond T Bartus, Tiffany L Baumann, Joao Siffert, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Neurology|February 18, 2009
Can we achieve neuroprotection with currently available anti-parkinsonian interventions?C Warren Olanow
Neurology|May 24, 2006
Rationale for considering that propargylamines might be neuroprotective in Parkinson's diseaseC Warren Olanow
Neurology|March 23, 2002
The role of dopamine agonists in the treatment of early Parkinson's diseaseC Warren Olanow
Neurology|May 24, 2006
The pathogenesis of cell death in Parkinson's diseasePeter Jenner, C Warren Olanow
Neurology|January 14, 2004
Continuous dopaminergic stimulation in early and advanced Parkinson's diseaseFabrizio Stocchi, C Warren Olanow
Neurology|January 14, 2004
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?C Warren Olanow, Fabrizio Stocchi
Neurology|May 28, 2009
The scientific and clinical basis for the treatment of Parkinson disease (2009)C Warren Olanow, Matthew B Stern, Kapil Sethi
Neurology|May 24, 2006
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's diseaseBiplob Dass, C Warren Olanow, Jeffrey H Kordower
Neurology|May 24, 2006
Proteasomal dysfunction in sporadic Parkinson's diseaseKevin St P McNaught, Tehone Jackson, Ruth JnoBaptiste, et al.
Neurology|April 12, 2013
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patientsRaymond T Bartus, Tiffany L Baumann, Joao Siffert, et al.
Pageof 2